ContractCollaboration and Commercialization Agreement • May 7th, 2018
Procella Therapeutics and Smartwise enter collaboration with AstraZeneca to develop novel cardiovascular and catheter-based therapies
COLLABORATION AND COMMERCIALIZATION AGREEMENTCollaboration and Commercialization Agreement • November 9th, 2020 • Senseonics Holdings, Inc. • Industrial instruments for measurement, display, and control • New York
THIS COLLABORATION AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is made as of August 9, 2020 (the “Effective Date”) by and between Senseonics Incorporated, a Delaware corporation (“Senseonics”), with its principal office and place of business at 20451 Seneca Meadows Parkway Germantown, MD 20876-7005, and Ascensia Diabetes Care Holdings AG, a Swiss company (“Ascensia” or “ADC”) with its principal office and place of business at Peter Merian-Strasse 90, 4052 Basel, Switzerland (each of Senseonics and Ascensia, a “Party” and together, the “Parties”).
THIRD AMENDMENT TO COLLABORATION AND COMMERCIALIZATION AGREEMENTCollaboration and Commercialization Agreement • August 8th, 2024 • Senseonics Holdings, Inc. • Industrial instruments for measurement, display, and control
This Third Amendment (the “Third Amendment”) to the Collaboration and Commercialization Agreement is entered into by and between Senseonics, Incorporated (“Senseonics”) and Ascensia Diabetes Care Holdings AG (“Ascensia”) (each of Senseonics and Ascensia, a “Party”, and together, the “Parties”) and is effective as of April 1st, 2024 (the “Third Amendment Effective Date”).
COLLABORATION AND COMMERCIALIZATION AGREEMENTCollaboration and Commercialization Agreement • June 26th, 2006 • Replidyne Inc • Pharmaceutical preparations • New York
Form 10-Q for the quarterly period ended September 30, 2020 Exhibit No. 10.1 Collaboration and Commercialization Agreement Filed November 9, 2020 File No. 001-37717Collaboration and Commercialization Agreement • February 23rd, 2021
We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.
CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY ***) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL FIRST AMENDMENT TO...Collaboration and Commercialization Agreement • August 9th, 2021 • Senseonics Holdings, Inc. • Industrial instruments for measurement, display, and control
This First Amendment (the “First Amendment”) to the Collaboration and Commercialization Agreement is entered into by and between Senseonics Incorporated (“Senseonics”) and Ascensia Diabetes Care Holdings AG (“Ascensia”) (each of Senseonics and Ascensia, a “Party”, and together, the “Parties”) and is effective as of March 31, 2021 (the “First Amendment Effective Date”).
COLLABORATION AND COMMERCIALIZATION AGREEMENTCollaboration and Commercialization Agreement • April 5th, 2006 • Replidyne Inc • New York
